Investor Relations
Developing Novel Therapies to Destroy Cancer
Filings & Shareholder Info

As of July 31, 2022, Briacell determined that it no longer qualified as a “foreign private issuer” as such term is defined in Rule 405 under the Securities Act. This means that, as of August 1, 2022, the Company has been required to comply with all of the periodic disclosure requirements of the Securities Exchange Act of 1934 applicable to U.S. domestic issuers, such as Forms 10-K, 10-Q and 8-K, rather than the forms the Company has filed with the Securities and Exchange Commission (“SEC”) in the past, as a foreign private issuer, such as Forms 40-F and 6-K. Accordingly, the Company is now required to prepare its financial statements filed with the SEC in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).

Annual General and Special Meeting 2023
Form of Proxy
Final Proxy Statement
Lumi AGM - Virtual Meeting Guide
Voting Instruction Form
BriaCell Therapeutics Corp. Annual Report on Form 10K
SEDAR Filings
Annual MDA
Annual FS
For additional SEDAR Filings, please visit
Shareholder Info
Computershare Trust Company Inc.
3200 Cherry Creek Drive South
Denver, CO 80209
CUSIP Number: 10778Y302

CUSIP Number: 10778Y112

CUSIP Number: 10778Y302
Corporate Office- Canada

Suite 300 - Bellevue Centre, 235 -15th Street,
West Vancouver, BC V7T 2X1

Tel: 604-921-1810
Fax: 604-921-1898

Corporate Office- US

2929 Arch Street, 3rd Floor
Philadelphia, PA 19104

Tel: 1-888-485-6340
Fax: 424-245-3719
Copyright 2021 © Briacell.| All rights reserved | XML Sitemap | HTML Sitemap